


Patamostat mesylate

Cat. No.:	HY-114080A
CAS No.:	114568-32-0
Molecular Formula:	C ₂₁ H ₂₄ N ₄ O ₇ S ₂
Molecular Weight:	508.57
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Patamostat (E-3123) mesylate is a potent protease inhibitor. Patamostat mesylate potently inhibits trypsin, plasmin and thrombin with IC ₅₀ s of 39 nM, 950 nM and 1.9 μM, respectively. Patamostat mesylate may possess suppressing effects on pathogenesis and development of acute pancreatitis ^{[1][2]} .								
IC₅₀ & Target	IC ₅₀ : 39 nM (trypsin), 950 nM (plasmin) and 1.9 μM (thrombin) ^[1]								
In Vivo	<p>Patamostat mesylate (intravenous infusion) at 0.03-0.3 mg/kg in rats or at 0.3-3.0 mg/kg in rabbits reduces mortality after the induction of pancreatitis in a dose-dependent manner^[1].</p> <p>Patamostat mesylate (1.0-3.0 mg/kg; intravenous infusion) reduces the increases of serum trypsin and lipase activities in dogs with pancreatitis^[1].</p> <p>Patamostat mesylate (2 mg/kg per h; continuous infusion) improves almost all parameters, including mortality rate, serum and ascitic fluid amylase levels, plasma endotoxin and serum FDP levels, and distribution of lysosomal enzyme in male Wistar rats^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Wistar rats weighing about 350 g^[2]</td> </tr> <tr> <td>Dosage:</td> <td>2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Continuous infusion per h for 1 h</td> </tr> <tr> <td>Result:</td> <td>Significantly improved the survival rate.</td> </tr> </table>	Animal Model:	Male Wistar rats weighing about 350 g ^[2]	Dosage:	2 mg/kg	Administration:	Continuous infusion per h for 1 h	Result:	Significantly improved the survival rate.
Animal Model:	Male Wistar rats weighing about 350 g ^[2]								
Dosage:	2 mg/kg								
Administration:	Continuous infusion per h for 1 h								
Result:	Significantly improved the survival rate.								

REFERENCES

[1]. K Miyamoto, et al. [Effects of E-3123, a New Protease Inhibitor, on Several Protease Activities and on Experimental Acute Pancreatitis]. Nihon Yakurigaku Zasshi. 1988 May;91(5):285-93.

[2]. T Hirano, et al. Protective Effect of a Cephalosporin, Shiomarin, Plus a New Potent Protease Inhibitor, E3123, on Rat Taurocholate-Induced Pancreatitis. J Gastroenterol Hepatol. Jan-Feb 1993;8(1):52-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA